Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Fletcher

Showing results (241-250 of 326) with videos related to

Pageof 33
Sort By:
Pharmacotherapy|March 28, 2025
Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluidSean N Avedissian, Ying Mu, Caitlyn McCarthy, et al.
African Journal of Laboratory Medicine|August 16, 2021
Cross-validation of a high-performance liquid chromatography nevirapine plasma assay in a resource-limited setting in ZimbabweFaithful Makita-Chingombe, Anthony T Podany, Timothy Mykris, et al.
Pediatrics|April 2, 1999
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 TeamM W Kline, S Blanchard, C V Fletcher, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
The Journal of Allergy and Clinical Immunology|March 6, 2007
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected childrenCourtney V Fletcher, Jaime G DeVille, Pearl M Samson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2006
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyHeather J Ribaudo, David W Haas, Camlin Tierney, et al.
Open Forum Infectious Diseases|June 6, 2018
Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV InfectionMeghan Rothenberger, John E Wagner, Ashley Haase, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1996
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSH H Balfour, C V Fletcher, A Erice, et al.
Contraception|February 14, 2023
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic studyLauren R Cirrincione, Shadia Nakalema, Catherine A Chappell, et al.
The Journal of Infectious Diseases|August 27, 2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359Roy M Gulick, X Joan Hu, Susan A Fiscus, et al.
Pageof 33

Showing results (241-250 of 326) with videos related to

Sort By:
Pageof 33
Pharmacotherapy|March 28, 2025
Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluidSean N Avedissian, Ying Mu, Caitlyn McCarthy, et al.
African Journal of Laboratory Medicine|August 16, 2021
Cross-validation of a high-performance liquid chromatography nevirapine plasma assay in a resource-limited setting in ZimbabweFaithful Makita-Chingombe, Anthony T Podany, Timothy Mykris, et al.
Pediatrics|April 2, 1999
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 TeamM W Kline, S Blanchard, C V Fletcher, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
The Journal of Allergy and Clinical Immunology|March 6, 2007
Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected childrenCourtney V Fletcher, Jaime G DeVille, Pearl M Samson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2006
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group StudyHeather J Ribaudo, David W Haas, Camlin Tierney, et al.
Open Forum Infectious Diseases|June 6, 2018
Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV InfectionMeghan Rothenberger, John E Wagner, Ashley Haase, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1996
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSH H Balfour, C V Fletcher, A Erice, et al.
Contraception|February 14, 2023
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic studyLauren R Cirrincione, Shadia Nakalema, Catherine A Chappell, et al.
The Journal of Infectious Diseases|August 27, 2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359Roy M Gulick, X Joan Hu, Susan A Fiscus, et al.
Pageof 33